What company did PharmaEssentia decide to acquire and for how much in NT dollars?

PharmaEssentia decided to acquire 100% of FORUS shares for NT$1.15 billion to strengthen its North American market presence.

When did PharmaEssentia sign a commercial licensing agreement with FORUS for Ropeg in Canada?

PharmaEssentia signed a commercial licensing agreement with FORUS for its new drug Ropeg in Canada in 2024.

What program did Health Canada include Ropeg in during the first quarter of 2025?

Health Canada included Ropeg in its 'Special Access Program' in the first quarter of 2025 due to strong local market demand.

When did FORUS submit an application for Ropeg for Polycythemia Vera in Canada and when is approval expected?

FORUS submitted an application for Ropeg for Polycythemia Vera in Canada in July 2025, with approval expected in the third quarter of this year.

What new indication for Ropeg is FORUS preparing to apply for in Canada after Polycythemia Vera?

After Polycythemia Vera, FORUS is preparing to submit an application for Ropeg for Essential Thrombocythemia in Canada.

AI News NQ Analysis

PharmaEssentia Acquires Canadian Partner for NT$1.15 Billion, Strengthening North American Market Presence

NQ Score 100/100

AI Summary (NQ-processed)

PharmaEssentia's board approved the acquisition of 100% equity in its Canadian partner, FORUS, for NT$1.15 billion, aiming to bolster its North American market strategy. FORUS has a strong presence in Canada's hematology and oncology treatment sectors with established market channels. PharmaEssentia's new drug, Ropeg, was included in Health Canada's 'Special Access Program' in Q1 2025 and is expected to receive approval for Polycythemia Vera (PV) in Q3 this year. This acquisition will integrate Canadian regulatory, marketing, and sales resources, accelerating the commercialization of Ropeg and future products.

AI analysis data is not yet available.

Frequently Asked Questions

Q: What company did PharmaEssentia decide to acquire and for how much in NT dollars?: A: PharmaEssentia decided to acquire 100% of FORUS shares for NT$1.15 billion to strengthen its North American market presence.
Q: When did PharmaEssentia sign a commercial licensing agreement with FORUS for Ropeg in Canada?: A: PharmaEssentia signed a commercial licensing agreement with FORUS for its new drug Ropeg in Canada in 2024.
Q: What program did Health Canada include Ropeg in during the first quarter of 2025?: A: Health Canada included Ropeg in its 'Special Access Program' in the first quarter of 2025 due to strong local market demand.
Q: When did FORUS submit an application for Ropeg for Polycythemia Vera in Canada and when is approval expected?: A: FORUS submitted an application for Ropeg for Polycythemia Vera in Canada in July 2025, with approval expected in the third quarter of this year.
Q: What new indication for Ropeg is FORUS preparing to apply for in Canada after Polycythemia Vera?: A: After Polycythemia Vera, FORUS is preparing to submit an application for Ropeg for Essential Thrombocythemia in Canada.